Contributions
Abstract: EP1418
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Experimental models
Erythropoietin (EPO) has neuroprotective effects in many models of damage and disease of the nervous system where neuroinflammation plays a substantial role, including experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis. The aim of this study was to assess the therapeutic effect of EPO during the course of EAE and to elucidate the EPO expression pattern in the spinal cord of Lewis rats with EAE. We used an EAE model induced in Lewis rats by immunization with myelin basic protein and complete Freund"s adjuvant (CFA) supplemented with Mycobacterium tuberculosis H37Ra. Control rats were immunized with CFA alone. Immunized rats were given recombinant human EPO (rhEPO) intraperitoneally at a dose of 5,000 U/kg for 7 consecutive days, either starting on day 3 post-immunization or on the day of clinical symptom onset (score ≥1). After immunization, the rats were observed daily for clinical signs of EAE. EPO expression was investigated by Western blot analysis and immunohistochemistry. Therapeutic administration of rhEPO to EAE rats once daily significantly reduced the disease severity and shortened the duration of paralysis in EAE rats, and reduced the accumulation of inflammatory cells in EAE spinal cords. The duration of paralysis was significantly reduced in early treatment group than control EAE rats treated with saline (4.6±0.4 days vs. 6.5±0.2 days). Furthermore, Western blot analysis showed that EPO expression was significantly elevated relative to controls in the rat spinal cord during the peak stage of EAE, and then decreased thereafter. Immunohistochemistry demonstrated that EPO was expressed in some neurons and glial cells. EPO immunoreactivity was detected in ED1-positive macrophages and astrocytes in EAE lesions. In summary, our study showed that EPO expression begins to increase at the start of EAE and that rhEPO administration may be therapeutic candidate for multiple sclerosis.
Disclosure: Sa-Yoon Kang: nothing to disclose
Abstract: EP1418
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Experimental models
Erythropoietin (EPO) has neuroprotective effects in many models of damage and disease of the nervous system where neuroinflammation plays a substantial role, including experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis. The aim of this study was to assess the therapeutic effect of EPO during the course of EAE and to elucidate the EPO expression pattern in the spinal cord of Lewis rats with EAE. We used an EAE model induced in Lewis rats by immunization with myelin basic protein and complete Freund"s adjuvant (CFA) supplemented with Mycobacterium tuberculosis H37Ra. Control rats were immunized with CFA alone. Immunized rats were given recombinant human EPO (rhEPO) intraperitoneally at a dose of 5,000 U/kg for 7 consecutive days, either starting on day 3 post-immunization or on the day of clinical symptom onset (score ≥1). After immunization, the rats were observed daily for clinical signs of EAE. EPO expression was investigated by Western blot analysis and immunohistochemistry. Therapeutic administration of rhEPO to EAE rats once daily significantly reduced the disease severity and shortened the duration of paralysis in EAE rats, and reduced the accumulation of inflammatory cells in EAE spinal cords. The duration of paralysis was significantly reduced in early treatment group than control EAE rats treated with saline (4.6±0.4 days vs. 6.5±0.2 days). Furthermore, Western blot analysis showed that EPO expression was significantly elevated relative to controls in the rat spinal cord during the peak stage of EAE, and then decreased thereafter. Immunohistochemistry demonstrated that EPO was expressed in some neurons and glial cells. EPO immunoreactivity was detected in ED1-positive macrophages and astrocytes in EAE lesions. In summary, our study showed that EPO expression begins to increase at the start of EAE and that rhEPO administration may be therapeutic candidate for multiple sclerosis.
Disclosure: Sa-Yoon Kang: nothing to disclose